DEXWireNews

GBT Global Blood Therapeutics 15% Upside

Long
NASDAQ:GBT   None
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our App on Google Play! dexwirenews.com/APP

2) Text Message Notifications: dexwirenews.com/SMS

3) Telegram: t.me/DEXWireNews

4) Follow Us on our Social Networks
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.